- Home
- WATT vs INDP Comparison
WATT vs INDP Comparison
Compare WATT & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WATT
- INDP
- Stock Information
- Founded
- WATT 2012
- INDP 2000
- Country
- WATT United States
- INDP United States
- Employees
- WATT N/A
- INDP N/A
- Industry
- WATT Radio And Television Broadcasting And Communications Equipment
- INDP Biotechnology: Pharmaceutical Preparations
- Sector
- WATT Technology
- INDP Health Care
- Exchange
- WATT Nasdaq
- INDP Nasdaq
- Market Cap
- WATT 9.1M
- INDP 7.4M
- IPO Year
- WATT 2014
- INDP N/A
- Fundamental
- Price
- WATT $0.30
- INDP $0.50
- Analyst Decision
- WATT Strong Buy
- INDP Strong Buy
- Analyst Count
- WATT 2
- INDP 2
- Target Price
- WATT $2.25
- INDP $8.50
- AVG Volume (30 Days)
- WATT 882.0K
- INDP 75.0K
- Earning Date
- WATT 05-13-2025
- INDP 05-07-2025
- Dividend Yield
- WATT N/A
- INDP N/A
- EPS Growth
- WATT N/A
- INDP N/A
- EPS
- WATT N/A
- INDP N/A
- Revenue
- WATT $768,000.00
- INDP N/A
- Revenue This Year
- WATT $1,028.91
- INDP N/A
- Revenue Next Year
- WATT N/A
- INDP N/A
- P/E Ratio
- WATT N/A
- INDP N/A
- Revenue Growth
- WATT 62.02
- INDP N/A
- 52 Week Low
- WATT $0.12
- INDP $0.43
- 52 Week High
- WATT $2.70
- INDP $3.10
- Technical
- Relative Strength Index (RSI)
- WATT 52.88
- INDP 39.50
- Support Level
- WATT $0.24
- INDP $0.45
- Resistance Level
- WATT $0.28
- INDP $0.53
- Average True Range (ATR)
- WATT 0.04
- INDP 0.04
- MACD
- WATT 0.01
- INDP 0.01
- Stochastic Oscillator
- WATT 100.00
- INDP 66.67
About WATT Energous Corporation
Energous Corp has developed wireless power networks technology (WPNT), consisting of semiconductor chipsets, software controls, hardware designs and antennas, that enable radio frequency (RF) based charging for Internet of Things (IoT) devices. Its products include Transmitter IC & Module, Receivers IC, Transmitter System and other tools.
About INDP Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.